Dallas, TX 2/14/2008 12:15:01 AM
News / Finance

Oramed Pharmaceuticals (ORMP) advances in the development of an innovative insulin pill

To read the full article visit http://www.beaconequity.com/ – News and Commentary

 

Diabetes affects approximately 170 million people worldwide and according to the World Health Organization (WHO) is expected to affect 300 million by 2025. Globally, diabetes is ranked as the 4th leading cause of death in terms of disease. The US alone has 21 million people or 7% of the population suffering from diabetes. It is the 6th most common cause of death as recorded on US death certificates.

 

The global diabetes drugs treatment market is one of the largest segments of the pharmaceutical industry, which has grown by a CAGR of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2006. Overall anti-diabetic drug sales are expected to grow significantly over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase. In 2005, the United States accounted for about 50% of the world market.

 

To read the full article visit http://www.beaconequity.com/ – News and Commentary

 

BeaconEquity.com Daily Volume Leaders – Research in Motion (Nasdaq: RIMM), Starbucks (Nasdaq: SBUX), Cisco (Nasdaq: CSCO), Microsoft Corp. (Nasdaq: MSFT), Yahoo Inc (Nasdaq: YHOO), Oracle (Nasdaq: ORCL), Applied Materials (Nasdaq: AMAT), Apple Inc. (Nasdaq: AAPL), Dell Inc. (Nasdaq: DELL), and Ebay Inc. (Nasdaq: EBAY)